- Home
- DFIN vs XERS Comparison
DFIN vs XERS Comparison
Compare DFIN & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DFIN
- XERS
- Stock Information
- Founded
- DFIN 1983
- XERS 2005
- Country
- DFIN United States
- XERS United States
- Employees
- DFIN N/A
- XERS N/A
- Industry
- DFIN Other Consumer Services
- XERS Biotechnology: Pharmaceutical Preparations
- Sector
- DFIN Consumer Discretionary
- XERS Health Care
- Exchange
- DFIN Nasdaq
- XERS Nasdaq
- Market Cap
- DFIN 1.4B
- XERS 1.3B
- IPO Year
- DFIN N/A
- XERS 2018
- Fundamental
- Price
- DFIN $45.26
- XERS $9.94
- Analyst Decision
- DFIN Strong Buy
- XERS Strong Buy
- Analyst Count
- DFIN 3
- XERS 7
- Target Price
- DFIN $65.67
- XERS $9.43
- AVG Volume (30 Days)
- DFIN 362.9K
- XERS 2.2M
- Earning Date
- DFIN 10-29-2025
- XERS 11-06-2025
- Dividend Yield
- DFIN N/A
- XERS N/A
- EPS Growth
- DFIN N/A
- XERS N/A
- EPS
- DFIN 1.12
- XERS N/A
- Revenue
- DFIN $750,800,000.00
- XERS $246,025,000.00
- Revenue This Year
- DFIN N/A
- XERS $43.89
- Revenue Next Year
- DFIN $4.66
- XERS $20.40
- P/E Ratio
- DFIN $41.34
- XERS N/A
- Revenue Growth
- DFIN N/A
- XERS 35.62
- 52 Week Low
- DFIN $37.80
- XERS $2.82
- 52 Week High
- DFIN $69.93
- XERS $10.03
- Technical
- Relative Strength Index (RSI)
- DFIN 33.97
- XERS 72.48
- Support Level
- DFIN $44.43
- XERS $9.11
- Resistance Level
- DFIN $46.57
- XERS $9.97
- Average True Range (ATR)
- DFIN 2.11
- XERS 0.37
- MACD
- DFIN -0.69
- XERS 0.04
- Stochastic Oscillator
- DFIN 12.08
- XERS 85.05
About DFIN Donnelley Financial Solutions Inc.
Donnelley Financial Solutions Inc is a risk and compliance solutions company. The company provides regulatory filing and deal solutions via its software-as-a-service, technology-enabled services, and print and distribution solutions to public and private companies, mutual funds, and other regulated investment firms. The company operates in four segments: Capital Markets - Software Solutions, Capital Markets - Compliance and Communications Management, Investment Companies - Software Solutions and Investment Companies - Compliance and Communications Management. Its geographical segments are the United States( USA), Europe, Asia, Canada, and others, of which the USA accounts for the vast majority of its total revenue.
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offer Recorlev for the treatment of Cushing's syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis (PPP).